pantoprazole and sulfasalazine
pantoprazole has been researched along with sulfasalazine in 8 studies
Research
Studies (8)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Amidon, GL; Dahan, A | 1 |
Adkison, KK; Gross, AS; Humphreys, JE; Koo, SH; Lee, DY; Lee, EJ; Li, L; Lou, Y; Mehta, AA; Polli, JW; Vaidya, SS | 1 |
Abe, K; Ando, O; Imaoka, T; Karibe, T | 1 |
Reviews
2 review(s) available for pantoprazole and sulfasalazine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Other Studies
6 other study(ies) available for pantoprazole and sulfasalazine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Colon; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Indoles; Indomethacin; Intestinal Absorption; Intestine, Small; Kinetics; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pantoprazole; Perfusion; Permeability; Propionates; Quinolines; Rats; Rats, Wistar; Sulfasalazine | 2009 |
Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biotransformation; Chromatography, High Pressure Liquid; Cross-Over Studies; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Genotype; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Neoplasm Proteins; Pantoprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Spectrophotometry, Ultraviolet; Sulfasalazine; Young Adult | 2010 |
Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Availability; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Curcumin; Cytochrome P-450 CYP3A; Female; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lapatinib; Macaca fascicularis; Male; Midazolam; Neoplasm Proteins; Pantoprazole; Quinazolines; Rosuvastatin Calcium; Sulfasalazine; Terfenadine | 2018 |